eventu leverag
ew annual investor day thursday tavr see strong growth low risk
approv feed demandand updat tavr tracker publish today show
continu good result year past focu sustain
growth aortic progress mitral tricuspid trajectori margin gain
current market size like chang near-term guidanc could revis
upward given recent trend pt
analyst meet thursday sustain aortic growth first key tavr strong
patch growth low risk approv feed demandand updat tavr
tracker publish today show continu strong result saw us tavr
growth world-wide tracker suggest see similar result
year past focu meet sustain growth
aortic includ program improv diagnosi treatment patient market
expand trial like earli tavr expand ncd pace new center
add geograph expans includ continu effort japan progress toward
open china updat next gener systemsoffset posit
could updat view competit though given recent data present
could swing posit ew sign price pressur particularli
europ pocket pressur open recent past
exhibit ew updat tavr tmvr market size investor day
aortic market size near-term guidanc recent updat market size
given last year pattern
compani updat view exhibit expect see chang
said view conserv outlook continu model
ew outlook compound-annual-growth-rate tavr suggest also note ew
offer tavr market would look like market
closer year short term strong ew offer
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
tavrtmvrmitr dmr/fmr us preval tricuspid us preval tavr exceed dmr/fmr us preval tricuspid us preval tavr grow tricuspid reach tavr grow januari tavr grow tricuspid reach tavr exceed tavr exceed mitral dmr us preval tavr reach tricuspid reach global tavr exceed tricuspid reach view low doubl digit growth tavr market easier comp
like well though gener outlook seem conserv given recent
trend updat focu
pleas see import disclosur inform page report
edward tavr market leader develop
key driver growth valuat
us growth remain robust
progress mitral continu could substanti
pt dcf base translat
price
signific expans patient popul
market share
forecast new
technolog label expans
earlier commerci rapid market
develop mitral
upsid tavr market growth share assumpt
faster tmvr market develop assum dcf
would support upsid translat
sale premium high-growth peer
slower adopt tavr
flatten penetr us and/or price
declin competit increas
inroad competitor tavr program lower ew
delays/setback mitral
conserv assumpt dcf model point
stock price translat
sale discount high-growth peer
anticip strong adopt tavr ew
sapien valv next sever year base
posit clinic data technolog advanc
rate extent tavr adopt remain key
variabl though uptak market size thu far
exceed even bullish forecast
mitral could substanti expand address
market transcathet valv
low-risk fda clearanc tavr
clinic regulatori commerci develop
edward competitor tavr program
progress penetr global tavr market
progress mitral pipelin program
pleas see import disclosur inform page report
updat mitral/tricuspid second key tmvr earli signific opportun
ew commentari mitral littl disappoint took target
board note measur earli launch pascal strategi
maintain premium price europ main culprit revenu expect
doubl model slower roll-out think
behind strategi like focal point thursday ew continu enrol
us trial pascal clasp iid dmr recent initi clasp iif fmr
pivot trial enrol patient total expect primari complet date
decemb accord clinicaltri gov ew provid timelin pascal
approv us market focu updat program beyond
pascal includ cardioband repair evoqu sapien replac
expect recent updat replac us pivot trial
slate begin year-end tricuspid ew receiv fda approv initi clasp iitr
pascal patient symptomat sever tricuspid regurgit expect
begin year-end second trial cardioband tricuspid posit expect
start soon well
tmvr market current annual close almost abbott
mitraclip half us half ou howev potenti multipl
come year ew peg tmvr/tmtt model global tmvr
market grow tmvr note septemb
higher forecast offer ew though note trajectori larg
mirror seen tavr first ten year market
profit third key despit fastest growth part busi tavr
tmvr carri higher corpor gross margin inher leverag
concentr group custom us current tavr center
come line continu model less year oper
margin expans year see one-tim headwind fx
hedg gain help gross margin sg stay elev given
tmvr develop invest new center overtim inher leverag
model start flow updat pace margin gain rel
invest remain import consider expect ew keep
pace invest high good indic confid sale growth outlook
leverag compani investor need support stori
number valuat overal thesi ew aortic market prove bigger
contribut growth longer current expect eventu crest
slow competit partial respons panacea mitral tricuspida
start contribut ew could see second act even bigger first underli
sustain top-line growth margin stori increasingli come focu
provid cushion outlook rais price target
dcf base chang behind updat increas year oper
margin assumpt target also sale line current forward
multipl peer
pleas see import disclosur inform page report
recent headlin aha posit tavr ew discuss detail
two late-break present aha novemb posit read
global tavr opportun well ew share market first france-tavi
propensity-match analysi found use corevalv self-expand
valv associ higher risk pvr mortal compar ew balloon-
expand valv second recoveri prospect random open-label trial
show earli surgic valv replac savr low-surg risk patient
patient popul enrol recoveri nearli ident ew on-going early-
tavr trial investig earli tavr intervent vs clinic monitor low-risk
france-tavi registri show se-thv higher risk vs ew be-thv late
break present aha also publish circul reveal
use self-expand transcathet heart valv se-thv associ higher
risk balloon-expand thv be-thv prospect non-random two-year
france-tavi registri includ patient undergo be-thv ew sapien-
valv se-thv corevalv sever
aortic stenosi tavr center paper conclud use se-
thv associ higher risk paravalvular regurgit pvr vs
higher in-hospit mortal vs all-caus mortal vs
compar ew be-thv via propensity-match import note howev
trial non-random use evolut evolut valv
recoveri show earli savr better watch wait low risk asymptomat
sever patient result recoveri trial present late break
session aha show earli surgic valv replac savr low-
surgic risk patient safer benefici standard care clinic
monitor symptom develop eight-year prospect open-label trial
enrol patient sever asymptomat aortic stenosi
random either earli savr watch wait primari
outcom studi reveal earli savr improv operative/cardiovascular mortal
year year versu watch wait vs vs respect
addit all-caus mortal year vs hospit due
heart failur vs also improv earli surgeri group versu convent
monitor importantli result may chang aha/acc valvular heart guidelin
surgeri patient popul current indic class iib
usefulness/efficaci less well establish evidence/opinion also note
patient popul nearli ident ew on-going early-tavr trial
similarli prospect random open-label trial investig potenti
surviv benefit earli tavr intervent sapien versu clinic monitor
pleas see import disclosur inform page report
pleas see import disclosur inform page report
total growth sale gross ensestot oper oper oper expens inc incom incom tax ens incom growth dilut yr/yr sale tavr products/ growth ex fx ex fx return mitral yr/yr valv thvt yr/yr growth ex fx valv therapi yr/yr discontinu products/stock growth ex fx yr/yr discontinu growth ex fx yr/yr disc growth ex fx equiti research
edward lifesci provid product technolog treat advanc cardiovascular diseas offer product
transcathet treatment valvular heart diseas surgic valv devic critic care technolog
pt dcf base includ assumpt aortic mitral transcathet technolog target also
sale risk includ pipelin setback competit price
pt deriv use multipl ep estim premium peer though in-line recent multipl risk
delay libr mitraclip competit chines nutrit slow product recal
pt ep risk integr pipelin competit
raj denhoy certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
anthoni petron cfa certifi view express research report accur reflect person view
subject secur subject compani also certifi part compens directli indirectli
relat specif recommend view express research report
briana warschun certifi view express research report accur reflect person view subject
secur subject compani also certifi part compens directli indirectli relat
specif recommend view express research report
case jefferi employe analyst respons coverag financi instrument discuss
report receiv compens base part overal perform firm includ invest bank incom seek
updat research appropri variou regul may prevent us asid certain industri report publish
period basi larg major report publish irregular interv appropri analyst judgement
articl articl
steven desancti own share inc common share
jefferi group llc make market secur adr
explan jefferi rate
buy describ secur expect provid total return price appreci plu yield within period
hold describ secur expect provid total return price appreci plu yield plu minu within
under-perform describ secur expect provid total return price appreci plu yield minu less within
expect total return price appreci plu yield buy rate secur averag secur price consist
within period compani typic volatil overal stock market hold rate
pleas see import disclosur inform page report
